GSK adds to its trove of pos­i­tive da­ta for mul­ti­ple myelo­ma con­tender as ri­vals con­tin­ue to com­mand the spot­light

Glax­o­SmithK­line’s can­cer R&D team put up more pos­i­tive num­bers for its ADC be­lan­tam­ab mafodotin, one of its top pipeline prospects.

Flash­ing the re­sults just ahead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER